Obesity

Roche pens $2.5B pact for Hanmi’s muscle-conserving obesity drug

Roche took its obesity strategy into uncharted territory via a $190 million upfront payment for a clinical-stage UCN2 analog from South Korea’s Hanmi.

James Waldron Aug 24, 2026 4:42am

After trimming headcount, Aardvark drops trials as wait drags on

Aug 12, 2026 9:03am

Novo Nordisk’s CFO reflects on ‘pressure’ to drive growth

Aug 7, 2026 9:08am

Novo CEO accepts ‘couple of setbacks,’ hunts for bolt-on deals

Aug 5, 2026 8:00am

Amgen drops ph. 1 obesity drug, upping pressure on MariTide

Aug 4, 2026 4:01pm

Lilly triple-G drug hits 22% weight loss, cardio impact unclear

Jul 23, 2026 9:06am